Explorative Analysis of Treatment Outcomes of Levofloxacin- and Moxifloxacin-Based Regimens and Outcome Predictors in Ethiopian MDR-TB Patients: A Prospective Observational Cohort Study

References

• World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2018.
   Google Scholar
• World Health Organization. Global Tuberculosis Report. Geneva, Switzerland: World Health Organization; 2016.
   Google Scholar
• World Health Organization. Global Tuberculosis Report. Geneva, Switzerland:: World Health Organization; 2019.
   Google Scholar
• World Health Organization. Global tuberculosis report 2020, 2020: 1–232.
   Google Scholar
• Kang YA, Choi YJ, Cho YJ, et al. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology. 2006;11(6):793–798. doi:10.1111/j.1440-1843.2006.00948.x17052310
   PubMed Web of Science ®Google Scholar
• White VL, Moore-Gillon J. Resource implications of patients with multidrug resistant tuberculosis. Thorax. 2000;55(11):962–963. doi:10.1136/thorax.55.11.96211050268
   PubMed Web of Science ®Google Scholar
• Nathanson E, Gupta R, Huamani P, et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-plus initiative. Int J Tuberc Lung Dis. 2004;8(11):1382–1384.15581210
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global tuberculosis report. WHO/CDS/TB/2019.15. Geneva: World Health Organization; 2019.
   Google Scholar
• Aubry A, Pan XS, Fisher LM, et al. Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother. 2004;48:(4):1281–1288. doi:10.1128/AAC.48.4.1281-1288.200415047530
   PubMed Web of Science ®Google Scholar
• Asif M. An overview on fluoroquinolone drugs for the treatment of tubercular infection. Int J Biosen Bioelectron. 2017;2(1):33‒36. doi:10.15406/ijbsbe.2017.02.00012
   Google Scholar
• Rodriguez JC, Ruiz M, Lopez M, et al. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents. 2002;20(6):(464–7). doi:10.1016/S0924-8579(02)00239-X
   Web of Science ®Google Scholar
• Noel GJ, Natarajan J, Chien S, et al. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin Pharmacol Ther. 2003;73(2):4. doi:10.1016/S0009-9236(03)90373-012545138
   PubMed Web of Science ®Google Scholar
• Täubel J, Prasad K, Rosano G, et al. Effects of the fluoroquinolones moxifloxacin and levofloxacin on the QT subintervals: sex differences in ventricular repolarization. J Clin Pharmacol. 2020;60(3):400–408. doi:10.1002/jcph.153431637733
   PubMed Web of Science ®Google Scholar
• Wang JY, Lee LN, Lai HC, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure. J Antimicrob Chemother. 2007;59(5):860–865. doi:10.1093/jac/dkm06117412727
   PubMed Web of Science ®Google Scholar
• Caminero JA. Likelihood of generating MDR-TB and XDR-TB under adequate National Tuberculosis Control Programme implementation. Int J Tuberc Lung Dis. 2008;12(8):869–877.18647445
   PubMed Web of Science ®Google Scholar
• Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009;180(4):365–370. doi:10.1164/rccm.200901-0146OC19483111
   PubMed Web of Science ®Google Scholar
• Migliori GB, Lange C, Centis R, et al. Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J. 2008;31(6):1155–1159. doi:10.1183/09031936.0002870818515555
   PubMed Web of Science ®Google Scholar
• Kim HR, Hwang SS, Kim HJ, et al. Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis. 2007;45(10):1290–1295. doi:10.1086/52253717968823
   PubMed Web of Science ®Google Scholar
• Kim DH, Kim HJ, Park SK, et al. Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182(1):113–119. doi:10.1164/rccm.200911-1656OC20224066
   PubMed Web of Science ®Google Scholar
• Srivastava S, Pasipanodya JG, Meek C, et al. Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis. 2011;204(12):1951–1959. doi:10.1093/infdis/jir65822021624
   PubMed Web of Science ®Google Scholar
• Jonsson EN, Karlsson MO. Xpose–an S-PLUS based population PK/PD model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58(1):51–64. doi:10.1016/S0169-2607(98)00067-410195646
   PubMed Web of Science ®Google Scholar
• Mohamed S, Fazlin A. Pharmacokinetic and pharmacodynamic modeling of antibiotics and bacterial drug resistance. Dig Compr Summ Upps Diss Fac Pharm. 2013;170:77.
   Google Scholar
• McIlleron H, Rustomjee R, Vahedi M, et al. Reduced antituberculosis drug concentrations in HIV-infected patients Who are men or have low weight: implications for international dosing guideline. Antimicrob Agents Chemother. 2012;56(6):3232–3238. doi:10.1128/AAC.05526-1122411614
   PubMed Web of Science ®Google Scholar
• Chigutsa E, Patel K, Denti P, et al. A time-to-event pharmacodynamic model describing treatment response in patients with pulmonary tuberculosis using days to positivity in automated liquid mycobacterial culture. Antimicrob Agents Chemother. 2013;57(2):789–795. doi:10.1128/AAC.01876-1223183433
   PubMed Web of Science ®Google Scholar
• Chen J, Chen Z, Li Y, et al. Characterization of gyrA and gyrB mutations and fluoroquinolone resistance in Mycobacterium tuberculosis clinical isolates from Hubei Province, China. Braz J Infect Dis. 2012;16(2):136–141. doi:10.1016/s1413-8670(12)70294-522552454
   PubMed Web of Science ®Google Scholar
• Nies AS. Principles of therapeutics. In: Hardman JG, Limbird LE, editors. Goodman & Gilman’s the Pharmacological Basis of Therapeutics. New York: McGraw-Hill; 2001:45–66.
   Google Scholar
• Laxminarayan R, Heymann D. Challenges of drug resistance in the developing world. BMJ. 2012;344:e1567. doi:10.1136/bmj.e156722491075
   PubMed Web of Science ®Google Scholar
• Aung K, Van DA, Declercq E, et al. Successful ‘9-month Bangladesh regimen’for multidrug-resistant tuberculosis among over 500 consecutive patients. The Int J Tuberc Lung Dis. 2014;18(10):1180–1187. doi:10.5588/ijtld.14.010025216831
   PubMed Web of Science ®Google Scholar
• Curry International Tuberculosis Center and California Department of Public Health. Drug-Resistant Tuberculosis: A Survival Guide for Clinicians. 3rd ed. Available from: http://www.currytbcenter.ucsf.edu/sites/default/files/tb_sg3_book.pdf. Accessed November 6, 2018.
   Google Scholar
• World Health Organization. Rapid communication: key changes to treatment of multi-drug and rifampicin- resistant tuberculosis (MDR/RRTB); 2018. Available from: http://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf?ua=1. Accessed September, 2018.
   Google Scholar
• Piubello A, Harouna SH, Souleymane M, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. The Int J Tuberc Lung Dis. 2014;18(10):1188–1194. doi:10.5588/ijtld.13.007525216832
   PubMed Web of Science ®Google Scholar
• Kuaban C, Noeske J, Rieder H, Ait-Khaled N, Abena Foe J, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–524. doi:10.5588/ijtld.14.053525868018
   PubMed Web of Science ®Google Scholar
• Moodley R, Godec TR. Short-course treatment for multidrug resistant tuberculosis: the STREAM trials. Eur Respir Rev. 2016;25(139):29–35. doi:10.1183/16000617.0080-201526929418
   PubMed Web of Science ®Google Scholar
• Kang YA, Shim TS, Koh WJ, et al. Choice between levofloxacin and moxifloxacin and multidrug-resistant tuberculosis treatment outcomes. Ann Am Thorac Soc. 2016;13:3. doi:10.1513/AnnalsATS.201510-690BC
   Web of Science ®Google Scholar
• Koh WJ, Lee SH, Kang YA, et al. Comparison of levofloxacin vs. moxifloxacin for multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2013;188(7):858–864. doi:10.1164/rccm.201303-0604OC23927582
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO global lists of high burden countries for TB, multidrug/rifampicin-resistant TB (MDR/RR-TB) and TB/HIV, 2021–2025; 2021.
   Google Scholar
• Girum T, Muktar E, Lentiro K, et al. Epidemiology of multidrug resistant tuberculosis (MDR-TB) in Ethiopia: a systematic review and meta-analysis of the prevalence, determinants and treatment outcome. Trop Dis Travel Med Vaccines. 2018;4(1):5. doi:10.1186/s40794-018-0065-529942536
   PubMedGoogle Scholar
• Woldeyohannes D, Assefa T, Aman R, et al. Predictors of time to unfavorable treatment outcomes among patients with multidrug resistant tuberculosis in Oromia region, Ethiopia. PLoS One. 2019;14(10):e0224025. doi:10.1371/journal.pone.022402531665154
   PubMed Web of Science ®Google Scholar
• Alene KA, Viney K, McBryde ES, et al. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia. Trop Med Int Health. 2017;22(3):351–362. doi:10.1111/tmi.1282627978594
   PubMed Web of Science ®Google Scholar
• Meressa D, Hurtado RM, Andrews JR, et al. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study. Thorax. 2015;70(12):1181–1188. doi:10.1136/thoraxjnl-2015-20737426506854
   PubMed Web of Science ®Google Scholar
• World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, Switzerland: World Health Organization; 2014.
   Google Scholar
• National Institute of Allergy and Infectious Diseases National Institutes of Health, US Department of Health and Human Services. Division of AIDS (DAIDS) table for grading the severity of adult and pediatric adverse events. Corrected Version 2.1; July, 2017.
   Google Scholar
• GLI. Line probe assays for drug resistant tuberculosis detection Interpretation and reporting guide for laboratory staff and clinicians (revised June 2018). Global Laboratory Initiative; 2017. Available from: http://www.stoptb.org/wg/gli/assets/documents/LPA_test_web_ready.pdf. Accessed December 12, 2021.
   Google Scholar
• Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–209. doi:10.1016/S2213-2600(15)00036-325726085
   PubMed Web of Science ®Google Scholar
• Peloquin CA, Hadad DJ, Molino LP, et al. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother. 2008;52:852–857. doi:10.1128/AAC.01036-0718070980
   PubMed Web of Science ®Google Scholar
• Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016;14(5):298–313. doi:10.1016/j.gpb.2016.03.00827729266
   PubMed Web of Science ®Google Scholar
• Roden DM, George JAL. The genetic basis of variability in drug responses. Nat Rev Drug Discov. 2002;1(1):37–44. doi:10.1038/nrd70512119608
   PubMed Web of Science ®Google Scholar
• Pirmohamed M. Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J. 2006;8(1):E20–6. doi:10.1208/aapsj08010316584129
   PubMed Web of Science ®Google Scholar
• Shah RR. Inter-ethnic differences in drug response: implications for drug development and complying with drug regulation. Clin Res Regul Aff. 2015;32(3):88–98. doi:10.3109/10601333.2015.1064131
   Google Scholar
• Naidoo A, Ramsuran V, Chirehwa M, et al. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis. Pharmacogenomics. 2018;19(1):17–29. doi:10.2217/pgs-2017-014429210323
   PubMed Web of Science ®Google Scholar
• Tola H, Holakouie-Naieni K, Mansournia MA, et al. National treatment outcome and predictors of death and treatment failure in multidrug-resistant tuberculosis in Ethiopia: a 10-year retrospective cohort study. BMJ Open. 2021;11(8):e040862. doi:10.1136/bmjopen-2020-040862
   Web of Science ®Google Scholar
• Yu MC, Chiang C-Y, Lee JJ, et al. Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up. Clin Infect Dis. 2018;67(2):869–877. doi:10.1093/cid/ciy06629718124
   PubMed Web of Science ®Google Scholar
• Javaid A, Ullah I, Masud H, et al. Predictors of poor treatment outcomes in multidrug-resistant tuberculosis patients: a retrospective cohort study. Clin Microbiol Infect. 2018;24(6):1155–1159. doi:10.1016/j.cmi.2017.09.012
   Web of Science ®Google Scholar
• Kang Y, Jo E-J, Eom JS, et al. Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-public–private mix periods. Tuberc Respir Dis. 2021;84(1):74–83. doi:10.4046/trd.2020.0093
   Web of Science ®Google Scholar
• Leveri TH, Lekule I, Mollel E, et al. Predictors of treatment outcomes among multidrug resistant tuberculosis patients in Tanzania. Tuberc Res Treat. 2019;2019:1–10.
   Google Scholar
• World Health Organization. Global tuberculosis report 2017. WHO; 2017:1–147.
   Google Scholar
• Ahmad N, Ahuja SD, Akkerman OW, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018;392(10150):821–834. doi:10.1016/S0140-6736(18)31644-130215381
   PubMed Web of Science ®Google Scholar
• Soeroto AY, Pratiwi C, Santoso P, Lestari BW. Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in West Java Indonesia: a retrospective cohort study. PLoS One. 2021;16(2):e0246284. doi:10.1371/journal.pone.024628433556094
   PubMed Web of Science ®Google Scholar
• Id AS, Gelaw B, Gebreyes W, Robinson R, Wang S, Tessema B. The burden of pre-extensively and extensively drug-resistant tuberculosis among MDR-TB patients in the Amhara region, Ethiopia. PLoS One. 2020;15(2):1–13. doi:10.1371/journal.pone.0229040.
   Web of Science ®Google Scholar
• Welekidan LN, Skjerve E, Dejene TA, et al. Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: a cross-sectional study. PLoS One. 2020;15(8):e0236362. doi:10.1371/journal.pone.023636232797053
   PubMed Web of Science ®Google Scholar
• Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–209.25726085
   PubMed Web of Science ®Google Scholar
• Duraisamy K, Mrithyunjayan S, Ghosh S, et al. Does alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome? A population-based study in Kerala, India. Ann Am Thorac Soc. 2014;11:5.
   Google Scholar
• Charoensakulchai S, Limsakul M, Saengungsumalee I, et al. Characteristics of poor tuberculosis treatment outcomes among patients with pulmonary tuberculosis in community hospitals of Thailand. Am J Trop Med Hyg. 2020;102(3):553–561. doi:10.4269/ajtmh.19-056431933460
   PubMed Web of Science ®Google Scholar
• Yoder MA, Lamichhane G, Bishai WR. Cavitary pulmonary tuberculosis: the Holy Grail of disease transmission. Curr Sci. 2004;86::74–81.
   Web of Science ®Google Scholar
• Murthy SE, Chatterjee F, Crook A, et al. Pretreatment chest x-ray severity and its relation to bacterial burden in smear positive pulmonary tuberculosis. BMC Med. 2018;16:73.29779492
   PubMed Web of Science ®Google Scholar
• Lee H, Sohn JW, Sim YS, Shin TR, Kim D-G, Choi H. Outcomes of extended duration therapy for drug-susceptible. Ann Transl Med. 2020;8(6):346. doi:10.21037/atm.2020.02.10432355790
   PubMed Web of Science ®Google Scholar
• Saeed W. Cavitating pulmonary tuberculosis: a global challenge. Clin Med. 2012;12(1):40–41. doi:10.7861/clinmedicine.12-1-40
   Web of Science ®Google Scholar
• Saeed W. Malignant tuberculosis. J Ayub Med Coll. 2006;18:1–2.
   Google Scholar
• Imamura Y, Murayama N, Okudaira N, Kurihara A. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug–Endogenous substance interaction involving the inhibition of renal secretion. Clin Pharmacol Ther. 2011;89(1):81–88. doi:10.1038/clpt.2010.23221124314
   PubMed Web of Science ®Google Scholar
• Udy AA, Roberts JA, Shorr AF, Boots RJ, Lipman J. Augmented renal clearance in septic and traumatized patients with normal plasma creatinine concentrations: identifying at-risk patients. Crit Care. 2013;17(1):R35. doi:10.1186/cc1254423448570
   PubMed Web of Science ®Google Scholar
• Claus BO, Hoste EA, Colpaert K, Robays H, Decruyenaere J, De Waele JJ. Augmented renal clearance is a common finding with worse clinical outcome in critically ill patients receiving antimicrobial therapy. J Crit Care. 2013;28(5):695–700. doi:10.1016/j.jcrc.2013.03.00323683557
   PubMed Web of Science ®Google Scholar
• Camargo MS, Mistro S, Oliveira MG, Passos LCS. Association between increased mortality rate and antibiotic dose adjustment in intensive care unit patients with renal impairment. Eur J Clin Pharmacol. 2019;75(1):119–126. doi:10.1007/s00228-018-2565-730276417
   PubMed Web of Science ®Google Scholar
• Okazaki O, Kojima C, Hakusui H, Nakashima M. Enantioselective disposition of ofloxacin in humans. Antimicrob Agents Chemother. 1991;35(10):2106–2109. doi:10.1128/AAC.35.10.21061759834
   PubMed Web of Science ®Google Scholar
• Hung CC, Kuo MC, Chang JM, Chen HC. Fluoroquinolone-induced acute interstitial nephritis in immunocompromised patients: two case reports. Nephrol Dial Transplant. 2006;21(1):238. doi:10.1093/ndt/gfi178
   Web of Science ®Google Scholar
• Wolfson JS, Hooper DC. Overview of fluoroquinolone safety. Am J Med. 1991;91(6):153S–161S. doi:10.1016/0002-9343(91)90330-Z1767803
   PubMed Web of Science ®Google Scholar
• Farid S, Mahmood M, Saleh OMA, et al. Clinical manifestations and outcomes of fluoroquinolone-related acute interstitial nephritis. Mayo Clin Proc. 2018;93(1):25–31. doi:10.1016/j.mayocp.2017.08.02429157532
   PubMed Web of Science ®Google Scholar
• Jeong I, Park JS, Cho YJ, et al. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels. J Korean Med Sci. 2015;30(2):167–172. doi:10.3346/jkms.2015.30.2.16725653488
   PubMed Web of Science ®Google Scholar
• Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003;167(11):1472–1477. doi:10.1164/rccm.200206-626OC12569078
   PubMed Web of Science ®Google Scholar
• Tostmann A, Boeree MJ, Aarnoutse RE, De lange WC, van der Ven AJ, Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol. 2008;23(2):192–202. doi:10.1111/j.1440-1746.2007.05207.x17995946
   PubMed Web of Science ®Google Scholar